8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Feb 3, 2026·SEC
Material company update
Jan 14, 2026·SEC
AngioDynamics, Inc.(ANGO)Earnings, Financials & Key Ratios
ANGO•NASDAQ
$11.05
$459M mkt cap·Price updated May 6, 2026
AboutAngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.Show more
- Revenue$292M-3.8%
- EBITDA-$14M+91.4%
- Net Income-$34M+81.6%
- EPS (Diluted)-0.83+81.9%
- Gross Margin53.92%+5.9%
- EBITDA Margin-4.84%+91.1%
- Operating Margin-13.66%+78.4%
- Net Margin-11.62%+80.8%
- ROE-17.5%+72.3%
- ROIC-22.93%+57.7%
ANGO Key Insights
AngioDynamics, Inc. (ANGO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ANGO Price & Volume
AngioDynamics, Inc. (ANGO) stock price & volume — 10-year historical chart
Loading chart...
ANGO Growth Metrics
AngioDynamics, Inc. (ANGO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.97%
5 Years2.06%
3 Years-2.57%
TTM7.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM87.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.97%
Return on Capital
10 Years-12.98%
5 Years-19.82%
3 Years-28.86%
Last Year-18.56%
ANGO Recent Earnings
AngioDynamics, Inc. (ANGO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 2, 2026EPS
$0.07
Est $0.11
+36.4%
Revenue
$78M
Est $77M
+2.2%
Q1 2026
Jan 6, 2026EPS
$0.15
Est $0.10
-50.0%
Revenue
$79M
Est $76M
+3.9%
Q4 2025
Oct 2, 2025EPS
$0.10
Est $0.14
+28.6%
Revenue
$76M
Est $76M
-0.8%
Q3 2025
Jul 15, 2025EPS
$0.03
Est $0.13
+76.9%
Revenue
$80M
Est $74M
+7.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 2, 2026 | $0.07vs $0.11+36.4% | $78Mvs $77M+2.2% |
| Q1 2026 | Jan 6, 2026 | $0.15vs $0.10-50.0% | $79Mvs $76M+3.9% |
| Q4 2025 | Oct 2, 2025 | $0.10vs $0.14+28.6% | $76Mvs $76M-0.8% |
| Q3 2025 | Jul 15, 2025 | $0.03vs $0.13+76.9% | $80Mvs $74M+7.9% |
Based on last 12 quarters of dataView full earnings history →
ANGO Peer Comparison
AngioDynamics, Inc. (ANGO) competitors in Surgical and interventional devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 | |
 ITGR | 2.97B | 86.29 | 29.86 | 7.57% | 7.67% | 8.23% | 0.80 | |
 CNMD | 1.15B | 37.32 | 24.72 | 5.16% | 4% | 5.4% | 0.81 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 | |
 BDX | 52.45B | 144.76 | 24.83 | 8.23% | 8.01% | 6.93% | 0.76 | |
 TMDX | 2.52B | 72.92 | 14.97 | 37.13% | 27.04% | 41.92% | 0.99 |
Compare ANGO vs Peers
AngioDynamics, Inc. (ANGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANGO Income Statement
AngioDynamics, Inc. (ANGO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 349.64M | 344.29M | 359.48M | 264.16M | 291.01M | 316.22M | 338.75M | 303.91M | 292.5M | 307.31M |
| Revenue Growth % | -1.14% | -1.53% | 4.41% | -26.52% | 10.17% | 8.66% | 7.13% | -10.28% | -3.76% | 7.26% |
| Cost of Goods Sold | 125.84M | 117.8M | 114.63M | 113.89M | 134.22M | 150.49M | 164.51M | 149.22M | 134.79M | 142.23M |
| COGS % of Revenue | 35.99% | 34.22% | 31.89% | 43.11% | 46.12% | 47.59% | 48.56% | 49.1% | 46.08% | - |
| Gross Profit | 143.95M▲ 0% | 143.86M▼ 0.1% | 156M▲ 8.4% | 150.27M▼ 3.7% | 156.79M▲ 4.3% | 165.73M▲ 5.7% | 174.25M▲ 5.1% | 154.7M▼ 11.2% | 157.71M▲ 1.9% | 165.07M▲ 0% |
| Gross Margin % | 41.17% | 41.78% | 43.4% | 56.89% | 53.88% | 52.41% | 51.44% | 50.9% | 53.92% | 53.72% |
| Gross Profit Growth % | -17.42% | -0.07% | 8.44% | -3.67% | 4.34% | 5.7% | 5.14% | -11.22% | 1.94% | - |
| Operating Expenses | 155.13M | 158.03M | 165.4M | 317.37M | 192.07M | 194.2M | 225.43M | 347.13M | 197.66M | 193.98M |
| OpEx % of Revenue | 44.37% | 45.9% | 46.01% | 120.14% | 66% | 61.41% | 66.55% | 114.22% | 67.58% | - |
| Selling, General & Admin | 110.22M | 108.54M | 116.13M | 116.51M | 117.22M | 133.75M | 144.25M | 143.98M | 145.23M | 150.21M |
| SG&A % of Revenue | 31.52% | 31.53% | 32.3% | 44.1% | 40.28% | 42.3% | 42.58% | 47.38% | 49.65% | - |
| Research & Development | 25.27M | 25.46M | 29.43M | 29.68M | 36.39M | 30.74M | 29.88M | 31.51M | 26.22M | 27.69M |
| R&D % of Revenue | 7.23% | 7.39% | 8.19% | 11.24% | 12.5% | 9.72% | 8.82% | 10.37% | 8.96% | - |
| Other Operating Expenses | 24.98M | 29.59M | 25.41M | 171.18M | 38.46M | 29.71M | 51.29M | 171.64M | 26.21M | 3M |
| Operating Income | -11.18M▲ 0% | -14.17M▼ 26.8% | -9.4M▲ 33.7% | -167.1M▼ 1678.4% | -35.28M▲ 78.9% | -28.47M▲ 19.3% | -51.18M▼ 79.8% | -192.44M▼ 276.0% | -39.95M▲ 79.2% | -28.91M▲ 0% |
| Operating Margin % | -3.2% | -4.12% | -2.61% | -63.26% | -12.12% | -9% | -15.11% | -63.32% | -13.66% | -9.41% |
| Operating Income Growth % | -1197.74% | -26.8% | 33.69% | -1678.4% | 78.88% | 19.31% | -79.77% | -275.99% | 79.24% | - |
| EBITDA | 13.64M | 8.99M | 16.48M | -143.29M | -9.37M | 878K | -20.31M | -164.72M | -14.15M | -4.92M |
| EBITDA Margin % | 3.9% | 2.61% | 4.59% | -54.25% | -3.22% | 0.28% | -5.99% | -54.2% | -4.84% | -1.6% |
| EBITDA Growth % | -53.19% | -34.05% | 83.3% | -969.29% | 93.46% | 109.37% | -2412.98% | -711.12% | 91.41% | 97.66% |
| D&A (Non-Cash Add-back) | 24.81M | 23.16M | 25.88M | 23.8M | 25.92M | 29.35M | 30.87M | 27.71M | 25.8M | 23.99M |
| EBIT | -11.46M | -14.2M | -9.6M | -167.23M | -35.19M | -18.22M | -18.68M | -33.84M | -24.06M | -27.37M |
| Net Interest Income | -2.84M | -3.06M | -5.1M | -907K | -861K | -688K | -2.7M | 1.61M | 978K | 32K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.61M | 978K | 138K |
| Interest Expense | 2.84M | 3.06M | 5.1M | 907K | 861K | 688K | 2.7M | 0 | 0 | 106K |
| Other Income/Expense | -3.12M | -3.09M | -5.31M | -1.04M | -769K | -1.48M | -3.26M | 797K | 5.92M | 1.2M |
| Pretax Income | -14.29M▲ 0% | -17.26M▼ 20.8% | -14.7M▲ 14.8% | -168.13M▼ 1043.6% | -36.05M▲ 78.6% | -29.95M▲ 16.9% | -54.44M▼ 81.8% | -191.64M▼ 252.0% | -34.03M▲ 82.2% | -27.71M▲ 0% |
| Pretax Margin % | -4.09% | -5.01% | -4.09% | -63.65% | -12.39% | -9.47% | -16.07% | -63.06% | -11.63% | -9.02% |
| Income Tax | -7.24M | -11.04M | -3.56M | -1.35M | -4.5M | -3.4M | -2M | -7.29M | -39K | -2K |
| Effective Tax Rate % | 50.67% | 63.93% | 24.19% | 0.8% | 12.49% | 11.36% | 3.66% | 3.8% | 0.11% | 0.01% |
| Net Income | -7.05M▲ 0% | 16.34M▲ 331.6% | 61.34M▲ 275.5% | -166.79M▼ 371.9% | -31.55M▲ 81.1% | -26.55M▲ 15.9% | -52.44M▼ 97.5% | -184.35M▼ 251.5% | -33.99M▲ 81.6% | -27.71M▲ 0% |
| Net Margin % | -2.02% | 4.74% | 17.06% | -63.14% | -10.84% | -8.4% | -15.48% | -60.66% | -11.62% | -9.02% |
| Net Income Growth % | 83.82% | 331.64% | 275.51% | -371.91% | 81.08% | 15.85% | -97.54% | -251.53% | 81.56% | 87.67% |
| Net Income (Continuing) | -7.05M | -6.23M | -11.15M | -166.79M | -31.55M | -26.55M | -52.44M | -184.35M | -33.99M | -27.71M |
| Discontinued Operations | 0 | 22.56M | 72.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.19▲ 0% | 0.44▲ 131.6% | 1.64▲ 272.7% | -4.37▼ 366.5% | -0.82▲ 81.2% | -0.68▲ 17.1% | -1.33▼ 95.6% | -4.59▼ 245.1% | -0.83▲ 81.9% | -0.67▲ 0% |
| EPS Growth % | 115.45% | 131.58% | 272.73% | -366.46% | 81.24% | 17.07% | -95.59% | -245.11% | 81.92% | 87.97% |
| EPS (Basic) | 0.19 | 0.44 | 1.64 | -4.37 | -0.82 | -0.68 | -1.33 | -4.59 | -0.83 | - |
| Diluted Shares Outstanding | 36.96M | 37.54M | 37.48M | 37.96M | 38.34M | 39.01M | 39.48M | 40.18M | 40.98M | 41.4M |
| Basic Shares Outstanding | 36.62M | 37.08M | 37.48M | 37.96M | 38.34M | 39.01M | 39.48M | 40.18M | 40.98M | 41.4M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ANGO Balance Sheet
AngioDynamics, Inc. (ANGO) balance sheet — assets, liabilities & shareholders' equity
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 153.91M | 168.03M | 315.29M | 152.91M | 140.88M | 143.34M | 163.54M | 193.25M | 168.32M | 161.35M |
| Cash & Short-Term Investments | 48.76M | 75.41M | 227.64M | 54.44M | 48.16M | 28.82M | 44.62M | 76.06M | 55.89M | 41.64M |
| Cash Only | 47.54M | 74.1M | 227.64M | 54.44M | 48.16M | 28.82M | 44.62M | 76.06M | 55.89M | 41.64M |
| Short-Term Investments | 1.22M | 1.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 46.36M | 39.4M | 43.58M | 34.17M | 37.32M | 56.5M | 52.83M | 50.01M | 43.14M | 44.43M |
| Days Sales Outstanding | 48.4 | 41.77 | 44.25 | 47.22 | 46.8 | 65.21 | 56.92 | 60.06 | 53.83 | 53.21 |
| Inventory | 54.51M | 39.27M | 40.07M | 59.91M | 48.61M | 51.39M | 55.33M | 60.62M | 62.01M | 65.57M |
| Days Inventory Outstanding | 158.1 | 121.69 | 127.59 | 191.99 | 132.2 | 124.65 | 122.75 | 148.27 | 167.9 | 162.27 |
| Other Current Assets | 2.76M | 12.15M | 2.2M | 1.55M | 1.76M | 2.2M | 7.26M | 2.58M | 3.07M | 9.71M |
| Total Non-Current Assets | 554.05M | 537.44M | 521.15M | 442.6M | 420.56M | 409.41M | 369.1M | 124.42M | 111.82M | 108.33M |
| Property, Plant & Equipment | 45.23M | 25.71M | 24.26M | 28.31M | 37.07M | 45.01M | 44.38M | 35.67M | 32.3M | 30.53M |
| Fixed Asset Turnover | 7.73x | 13.39x | 14.82x | 9.33x | 7.85x | 7.03x | 7.63x | 8.52x | 9.06x | 9.72x |
| Goodwill | 361.25M | 361.25M | 347.67M | 201.51M | 201.32M | 201.06M | 159.24M | 0 | 0 | 0 |
| Intangible Assets | 145.68M | 130.31M | 145.39M | 197.14M | 168.98M | 152.38M | 111.14M | 77.38M | 69.12M | 66.73M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.89M | 113.23M | 3.83M | 15.64M | 13.19M | 10.96M | 54.33M | 11.37M | 10.4M | 40.7M |
| Total Assets | 707.96M▲ 0% | 705.47M▼ 0.4% | 836.44M▲ 18.6% | 595.51M▼ 28.8% | 561.44M▼ 5.7% | 552.75M▼ 1.5% | 532.64M▼ 3.6% | 317.67M▼ 40.4% | 280.14M▼ 11.8% | 269.68M▲ 0% |
| Asset Turnover | 0.49x | 0.49x | 0.43x | 0.44x | 0.52x | 0.57x | 0.64x | 0.96x | 1.04x | 1.12x |
| Asset Growth % | -2.76% | -0.35% | 18.56% | -28.8% | -5.72% | -1.55% | -3.64% | -40.36% | -11.81% | -40.98% |
| Total Current Liabilities | 69.52M | 57.3M | 73.3M | 51.53M | 57.58M | 74.32M | 83.83M | 91.16M | 76.2M | 71.96M |
| Accounts Payable | 18.09M | 15.78M | 22.83M | 19.1M | 19.63M | 28.05M | 40.45M | 37.75M | 33.29M | 35.39M |
| Days Payables Outstanding | 52.46 | 48.88 | 72.69 | 61.2 | 53.38 | 68.03 | 89.74 | 92.34 | 90.15 | 83.93 |
| Short-Term Debt | 14.63M | 7.1M | 12.13M | 836K | 0 | 8.78M | 14.76M | 4.73M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.08M | 1.94M | 504K | 3.02M | 3.04M | 2.71M | 2.26M | 9.06M | 8.56M | 8.31M |
| Current Ratio | 2.21x | 2.93x | 4.30x | 2.97x | 2.45x | 1.93x | 1.95x | 2.12x | 2.21x | 2.21x |
| Quick Ratio | 1.43x | 2.25x | 3.75x | 1.80x | 1.60x | 1.24x | 1.29x | 1.46x | 1.40x | 1.40x |
| Cash Conversion Cycle | 154.03 | 114.58 | 99.14 | 178.01 | 125.62 | 121.84 | 89.93 | 115.99 | 131.59 | 131.54 |
| Total Non-Current Liabilities | 121.42M | 105.58M | 148.32M | 88.11M | 64.4M | 53.94M | 70.52M | 20.93M | 20.98M | 21.39M |
| Long-Term Debt | 91.32M | 86.62M | 124.41M | 40M | 20M | 25M | 49.82M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 26.11M | 17.17M | 14.54M | 24.06M | 19.95M | 16.04M | 12.81M | 4.85M | 4.07M | 16.88M |
| Other Non-Current Liabilities | 3.99M | 1.78M | 9.37M | 23.84M | 24.44M | 12.9M | 7.88M | 16.08M | 16.9M | 65.57M |
| Total Liabilities | 190.93M | 162.88M | 221.62M | 139.64M | 121.98M | 128.26M | 154.34M | 112.08M | 97.17M | 93.35M |
| Total Debt | 105.94M | 93.72M | 136.54M | 40.84M | 20M | 33.78M | 64.58M | 4.73M | 0 | 0 |
| Net Debt | 58.4M | 19.63M | -91.1M | -13.6M | -28.16M | 4.96M | 19.96M | -71.33M | -55.89M | -41.64M |
| Debt / Equity | 0.20x | 0.17x | 0.22x | 0.09x | 0.05x | 0.08x | 0.17x | 0.02x | - | 0.00x |
| Debt / EBITDA | 7.77x | 10.42x | 8.28x | - | - | 38.48x | - | - | - | -0.00x |
| Net Debt / EBITDA | 4.28x | 2.18x | -5.53x | - | - | 5.65x | - | - | - | 8.46x |
| Interest Coverage | -3.94x | -4.63x | -1.84x | -184.23x | -40.98x | -41.38x | -18.94x | - | - | -258.19x |
| Total Equity | 517.03M▲ 0% | 542.6M▲ 4.9% | 614.82M▲ 13.3% | 455.87M▼ 25.9% | 439.46M▼ 3.6% | 424.49M▼ 3.4% | 378.3M▼ 10.9% | 205.59M▼ 45.7% | 182.97M▼ 11.0% | 176.33M▲ 0% |
| Equity Growth % | 1.97% | 4.95% | 13.31% | -25.85% | -3.6% | -3.41% | -10.88% | -45.65% | -11% | -40.62% |
| Book Value per Share | 13.99 | 14.45 | 16.40 | 12.01 | 11.46 | 10.88 | 9.58 | 5.12 | 4.46 | 4.26 |
| Total Shareholders' Equity | 517.03M | 542.6M | 614.82M | 455.87M | 439.46M | 424.49M | 378.3M | 205.59M | 182.97M | 176.33M |
| Common Stock | 367K | 370K | 372K | 374K | 377K | 380K | 382K | 385K | 385K | 386K |
| Retained Earnings | -11.01M | 5.13M | 66.47M | -100.32M | -131.87M | -158.41M | -210.85M | -395.2M | -429.2M | -446.45M |
| Treasury Stock | -5.71M | -5.71M | -5.71M | -5.71M | -5.71M | -5.71M | -5.71M | -5.71M | -7.38M | -7.38M |
| Accumulated OCI | -1.32M | -952K | -1.35M | -1.34M | 3.15M | 1.36M | -4.72M | -4.37M | -2.02M | 998K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANGO Cash Flow Statement
AngioDynamics, Inc. (ANGO) cash flow — operating, investing & free cash flow history
| Line item | May'17 | May'18 | May'19 | May'20 | May'21 | May'22 | May'23 | May'24 | May'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 55.74M | 41.29M | 37.44M | -14.55M | 24.09M | -7.19M | 78K | -28.16M | -10.13M | -10.13M |
| Operating CF Margin % | 15.94% | 11.99% | 10.41% | -5.51% | 8.28% | -2.27% | 0.02% | -9.27% | -3.46% | - |
| Operating CF Growth % | 23.29% | -25.94% | -9.32% | -138.87% | 265.54% | -129.86% | 101.08% | -36200% | 64.03% | 372.38% |
| Net Income | 7.01M | 16.34M | 61.34M | -156.07M | -31.55M | -26.55M | -52.44M | -184.35M | -33.99M | -27.71M |
| Depreciation & Amortization | 24.81M | 23.16M | 25.88M | 23.8M | 25.92M | 29.35M | 30.87M | 27.71M | 25.8M | 23.99M |
| Stock-Based Compensation | 6.18M | 7.91M | 9.25M | 7.59M | 8.63M | 10.69M | 11.16M | 10.53M | 9.77M | 11.4M |
| Deferred Taxes | 4.43M | -8.95M | -2.65M | -1.57M | -4.8M | -3.71M | -2.31M | -7.97M | -988K | -464K |
| Other Non-Cash Items | -9.54M | 364K | -55.11M | 140.23M | 16.83M | 4.07M | 19.83M | 111.5M | 3.39M | 3.18M |
| Working Capital Changes | 24.86M | 2.46M | -1.26M | -28.55M | 9.07M | -21.05M | -7.03M | 14.42M | -14.11M | -16M |
| Change in Receivables | 8.48M | 5.04M | -3.18M | 11.92M | -4.16M | -17.15M | -1.3M | 7.89M | 23K | -1.46M |
| Change in Inventory | 687K | 5.74M | -1.43M | -18.84M | 11.54M | -2.8M | -8.2M | -9.41M | -1.35M | 483K |
| Change in Payables | 17.21M | -7.09M | 5.21M | -15.47M | 4.88M | 3.91M | 2.14M | 27.53M | -15.88M | -15.89M |
| Cash from Investing | -2.55M | -3.66M | 82.55M | -63.34M | -13.71M | -19.31M | -9.75M | 123.72M | -10.18M | -8.98M |
| Capital Expenditures | -3M | -2.39M | -3.12M | -7.24M | -5.19M | -4.3M | -3.81M | -2.52M | -4.46M | -3.73M |
| CapEx % of Revenue | 0.86% | 0.69% | 0.87% | 2.74% | 1.78% | 1.36% | 1.13% | 0.83% | 1.53% | - |
| Acquisitions | 0 | 0 | -84.92M | -55.76M | 0 | -3.6M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -1.26M | 169.24M | -350K | -8.52M | -11.41M | -5.93M | 126.23M | -5.71M | -5.26M |
| Cash from Financing | -37.98M | -11.55M | 33.93M | -95.24M | -16.99M | 7.68M | 25.42M | -64.25M | -255K | 1.43M |
| Debt Issued (Net) | -23.91M | -5M | 40M | -92.5M | -20M | 5M | 25M | -50M | 6.16M | -91K |
| Equity Issued (Net) | -1000K | 0 | 0 | 0 | 1000K | 1000K | 1000K | 752K | -1000K | 1.13M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -13.56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.67M | 0 |
| Other Financing | -516K | -6.55M | -6.07M | -2.74M | 0 | 0 | -751K | -15M | -4.75M | 390K |
| Net Change in Cash | 15.21M▲ 0% | 26.55M▲ 74.6% | 153.54M▲ 478.3% | -173.21M▼ 212.8% | -6.27M▲ 96.4% | -19.34M▼ 208.2% | 15.79M▲ 181.7% | 31.44M▲ 99.0% | -20.16M▼ 164.1% | -12.45M▲ 0% |
| Free Cash Flow | 52.74M▲ 0% | 37.63M▼ 28.7% | 34.32M▼ 8.8% | -22.14M▼ 164.5% | 18.91M▲ 185.4% | -11.49M▼ 160.8% | -4.27M▲ 62.8% | -33.93M▼ 693.8% | -14.59M▲ 57.0% | -9.33M▲ 0% |
| FCF Margin % | 15.09% | 10.93% | 9.55% | -8.38% | 6.5% | -3.63% | -1.26% | -11.16% | -4.99% | -3.04% |
| FCF Growth % | 33.12% | -28.65% | -8.79% | -164.5% | 185.4% | -160.78% | 62.81% | -693.78% | 56.99% | 68.5% |
| FCF per Share | 1.43 | 1.00 | 0.92 | -0.58 | 0.49 | -0.29 | -0.11 | -0.84 | -0.36 | -0.36 |
| FCF Conversion (FCF/Net Income) | -7.90x | 2.53x | 0.61x | 0.09x | -0.76x | 0.27x | -0.00x | 0.15x | 0.30x | 0.34x |
| Interest Paid | 2.97M | 3.19M | 5.12M | 413K | 731K | 562K | 2.58M | 0 | 185K | 0 |
| Taxes Paid | 102K | 36K | 426K | 682K | 313K | 329K | 342K | 455K | 800K | 0 |
ANGO Key Ratios
AngioDynamics, Inc. (ANGO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1.38% | 3.08% | 10.6% | -31.16% | -7.05% | -6.15% | -13.06% | -63.15% | -17.5% | -15.71% |
| Return on Invested Capital (ROIC) | -1.42% | -1.87% | -1.3% | -25.95% | -6.2% | -5.08% | -9.28% | -54.21% | -22.93% | -22.93% |
| Gross Margin | 41.17% | 41.78% | 43.4% | 56.89% | 53.88% | 52.41% | 51.44% | 50.9% | 53.92% | 53.72% |
| Net Margin | -2.02% | 4.74% | 17.06% | -63.14% | -10.84% | -8.4% | -15.48% | -60.66% | -11.62% | -9.02% |
| Debt / Equity | 0.20x | 0.17x | 0.22x | 0.09x | 0.05x | 0.08x | 0.17x | 0.02x | - | 0.00x |
| Interest Coverage | -3.94x | -4.63x | -1.84x | -184.23x | -40.98x | -41.38x | -18.94x | - | - | -258.19x |
| FCF Conversion | -7.90x | 2.53x | 0.61x | 0.09x | -0.76x | 0.27x | -0.00x | 0.15x | 0.30x | 0.34x |
| Revenue Growth | -1.14% | -1.53% | 4.41% | -26.52% | 10.17% | 8.66% | 7.13% | -10.28% | -3.76% | 7.26% |
ANGO SEC Filings & Documents
AngioDynamics, Inc. (ANGO) SEC filings — annual & quarterly reports (10-K, 10-Q)
ANGO Frequently Asked Questions
AngioDynamics, Inc. (ANGO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AngioDynamics, Inc. (ANGO) reported $307.3M in revenue for fiscal year 2025. This represents a 895% increase from $30.9M in 2002.
AngioDynamics, Inc. (ANGO) saw revenue decline by 3.8% over the past year.
AngioDynamics, Inc. (ANGO) reported a net loss of $27.7M for fiscal year 2025.
Dividend & Returns
AngioDynamics, Inc. (ANGO) has a return on equity (ROE) of -17.5%. Negative ROE indicates the company is unprofitable.
AngioDynamics, Inc. (ANGO) had negative free cash flow of $9.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More ANGO
AngioDynamics, Inc. (ANGO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates